摘要
目的:探讨阿仑膦酸钠加阿法骨化醇对绝经后骨质疏松患者骨密度及骨代谢标志物的改善作用。方法:选取2019年6月—2021年6月武穴市第二人民医院骨科收治的80例绝经后骨质疏松患者。采用随机数表法将患者分为观察组与对照组,各40例。对照组给予阿法骨化醇,观察组在对照组基础上加用阿仑膦酸钠,两组均持续用药6个月。比较两组治疗效果,治疗前后骨密度、骨代谢标志物、细胞因子及不良反应发生率。结果:观察组总有效率为97.50%,高于对照组的82.50%(P<0.05)。两组治疗前股骨粗隆、股骨颈、腰椎正位骨密度比较,差异均无统计学意义(P>0.05);观察组治疗后股骨粗隆、股骨颈、腰椎正位骨密度均高于对照组(P<0.05)。两组治疗前骨代谢标志物[抗酒石酸酸性磷酸酶5b(TRACP-5b)、骨钙素(BGP)、Ⅰ型胶原C端肽(CTX-Ⅰ)、骨碱性磷酸酶(BALP)]比较,差异均无统计学意义(P>0.05);观察组治疗后TRACP-5b、BGP、CTX-Ⅰ、BALP均低于对照组(P<0.05)。两组治疗前细胞因子[金属蛋白酶组织抑制因子1(TIMP-1)、基质金属蛋白酶-13(MMP-13)]比较,差异均无统计学意义(P>0.05);观察组治疗后TIMP-1高于对照组,MMP-13低于对照组(P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:绝经后骨质疏松患者在阿法骨化醇给药基础上加用阿仑膦酸钠,可提高总有效率,改善骨密度、骨代谢标志物及细胞因子水平,且具较高安全性,开展价值显著。
Objective: To investigate the improvement effect of Alendronate Sodium and Afacalcitol on bone mineral density and bone metabolic markers in patients with postmenopausal osteoporosis. Method: A total of 80 patients with postmenopausal osteoporosis who admitted to the Orthopedics Department of Wuxue Second People’s Hospital from June 2019 to June 2021 were selected, and they were divided into the observation group and the control group according to the random number table method, 40cases in each group. The control group was given Alfacalcidol, and the observation group was added with Alendronate Sodium on the basis of the control group, two groups were treated continuously for 6 months. The therapeutic effects, bone mineral density, bone metabolism markers and cytokines before and after treatment, and the incidence of adverse reactions were compared between two groups. Result: The total effective rate of the observation group was 97.50%, which was higher than 82.50% of the control group(P<0.05). There were no significant differences in femoral trochanter, femoral neck and bone mineral density of lumbar spine between two groups before treatment(P>0.05);the femoral trochanter, femoral neck and bone mineral density of lumbar spine in the observation group after treatment were higher than those in the control group(P<0.05). There were no significant differences in the bone metabolic markers [tartrate resistant phosphonatase 5b(TRACP-5b), osteocalcin(BGP), type Ⅰ collagen C-terminal peptide(CTX-Ⅰ) and bone basic phosphonatase(BALP)] between two groups before treatment(P>0.05);the TRACP-5b, BGP, CTX-Ⅰ and BALP in the observation group after treatment were lower than those in the control group(P<0.05). There were no significant differences in the cytokines [tissue inhibitor of metalloproteinase-1(TIMP-1) and matrix metalloproteinase-13(MMP-13)] between two groups before treatment(P>0.05);the TIMP-1 in the observation group after treatment was higher than that in the control group, the MMP-13 was lower than that in the control group(P<0.05). There was no significant difference in the adverse reaction rates between two groups(P>0.05). Conclusion: For patients with postmenopausal osteoporosis, the addition of Alendronate Sodium on the basis of Afacalcitol administration can improve the total effective rate, improve the levels of bone mineral density, bone metabolic markers and cytokines, and have high safety and significant development value.
作者
柯太平
KE Taiping(Wuxue Second People's Hospital,Wuxue 435400,China)
出处
《中外医学研究》
2023年第5期111-115,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
绝经
骨质疏松
阿仑膦酸钠
阿法骨化醇
骨密度
骨代谢标志物
Menopause
Osteoporosis
Alendronate Sodium
Alfacalcidol
Bone mineral density
Bone metabolism markers
